Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Amarin Corporation plc
< Previous
1
2
Next >
Amarin Reports Second Quarter 2023 Financial Results
August 02, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
July 31, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
July 26, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
July 25, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
July 20, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Appoints Patrick Holt as President and Chief Executive Officer
July 18, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
July 18, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
June 21, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Present at Two Upcoming Investor Conferences
June 01, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
June 01, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
May 12, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
April 19, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
April 17, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
April 04, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
March 16, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces Board Departures
March 06, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
March 06, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
March 05, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 01, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
February 28, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
February 28, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
ASX
CSLLY
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
February 27, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
February 27, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Present at Cowen's 43rd Annual Health Care Conference
February 22, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023
February 21, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE
February 17, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote “AGAINST” Sarissa’s Value-Destructive Proposals
February 16, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards
February 16, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote “AGAINST” All of Sarissa’s Proposals
February 13, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.